Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching
Authors' conclusion
In this study, including obese participants with poor glycaemic control, switching DPP-4 inhibitors to oral semaglutide showed more beneficial effects on both glycaemic and weight control, irrespective of age, body weight and diabetes duration. Therefore, we should bear in mind that it would be better to start using an oral semaglutide in clinical practice, particularly in obese participants with poor glycaemic control with DPP-4 inhibitors.
Study context
- Population
- Japanese patients with T2D on DPP-4i1:1 propensity score matched
- Participants
- 51 vs 51
- Exposure
- Switching from DPP-4i to oral semaglutide vs DPP-4i continuation
- Switchingn = 51
- DPP-4 inhibitor continuationn = 51reference
- Outcome
- Glycaemic control and metabolic parameters
- Follow-up
- 6 months
Methodological detailspre-post comparison (study 1), 1:1 propensity score matching (study 2)
- Pre-post comparison (study 1)
- 1:1 propensity score matching (study 2)
Main finding
As reported in the abstract
HbA1c significantly reduced, before to after switching
7.5% to 7.0%
BMI decreased, before to after switching
29.7 kg/m² to 28.8 kg/m²
Observational data: associations, not effects.
Further findings
Subgroup with poor glycaemic control
- Effects more clearly observed in participants with poor glycaemic control
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →